Gadopiclenol, initially invented by Guerbet with subsequent contribution of Bracco IP, is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity.1 The efficacy and safety of Gadopiclenol have been evaluated in MRI of the Central Nervous System, head and neck, thorax, abdomen, pelvis, and musculoskeletal system (refer to the approved USPI for full information).2 Details on Phase III clinical trials are available on www.ClinicalTrials.gov.

article

New contrast agent is officially available for use in hospitals and clinics

Bracco’s new MRI contrast agent is now available for use in hospitals and clinics, according to the company’s latest announcement.

Two doctors
article

Bracco Imaging Announces Global Collaboration Agreement with Guerbet for Gadopiclenol

Bracco Imaging announced a global strategic collaboration agreement with Guerbet for Gadopiclenol

Bracco Imaging_Guerbet: new agreement for Gadopiclenol
Article

Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol

Companies will collaborate on manufacturing and research and development for future indications, and will commercialize Gadopiclenol independently under separate brands.

Doctors

 

 

1) Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS)

Magnetic Resonance Imaging (MRI)

 

View​

 

 

2) Efficacy and Safety of Gadopiclenol for Body

Magnetic Resonance Imaging (MRI)

 

View